LAURA RIOS: Open Payments
NPI 1063288124 · LAS VEGAS, NV. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,373 in 109 payments from 20 companies in 2025. Trend: 2023 $0 · 2024 $1,977 · 2025 $2,373
Food & beverage: $2,373
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 19 | $404 |
| Bayer Healthcare Pharmaceuticals Inc. | 17 | $334 |
| Novartis Pharmaceuticals Corporation | 12 | $281 |
| Amgen Inc. | 10 | $260 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 10 | $226 |
| Calliditas Therapeutics US Inc. | 6 | $151 |
| Vifor Pharma, Inc. | 10 | $140 |
| Travere Therapeutics, Inc. | 3 | $106 |
| Mallinckrodt Hospital Products Inc. | 3 | $89 |
| AKEBIA THERAPEUTICS INC | 3 | $73 |
Products named: Kerendia, JYNARQUE, KRYSTEXXA, Fabhalta, JARDIANCE, TARPEYO, Veltassa, Vafseo.
Industry payments across NV — which companies pay providers there.
